TC
AMPE

TFS Capital’s Ampio Pharmaceuticals Inc. AMPE Stock Holding History

TFS Capital’s Portfolio AMPE Stock Details AMPE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-92
Closed -$98K – 1202
2014
Q3 		$98K Buy
+92
New +$155K 0.01% 973

Other funds holding AMPE

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TC
Talkot Capital Sausalito, California $73.7M AUM 8.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NFG
Noven Financial Group Denver, Colorado $123M AUM 5.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TFS Capital's AMPE Position: Q4 2014 in Review

TFS Capital sold out of Ampio Pharmaceuticals Inc. (AMPE) in Q4 2014, closing a stake of 92 shares — an estimated $98K sold.

TFS Capital first reported a position in AMPE in Q3 2014 and held it in 1 quarter. The position peaked at $98K in Q3 2014. 69 funds tracked by Wall St. Rank hold AMPE as of Q4 2014.

  • TFS Capital reported no remaining Ampio Pharmaceuticals Inc. position as of Q4 2014 after selling out during the quarter.
  • TFS Capital sold 92 Ampio Pharmaceuticals Inc. shares in Q4 2014, an estimated $98K.
  • TFS Capital first reported a position in Ampio Pharmaceuticals Inc. in Q3 2014 and held it in 1 quarter.
  • TFS Capital's Ampio Pharmaceuticals Inc. position peaked at $98K in Q3 2014.
  • 69 funds tracked by Wall St. Rank held Ampio Pharmaceuticals Inc. as of Q4 2014.

Based on TFS Capital's 13F filing for Q4 2014, filed 29 Jan 2015.